The virus may be a human immunodeficiency virus (HIV) such as HIV-1 or HIV-2.
The present invention relates to a new variety of retroviruses distinct from HIV-1 and HIV-2, designated HIV-LP.
A chimaeric protein which presents the CD4 receptor 5 binding site of HIV-1 or HIV-2 is useful as a vaccine against both HIV-1 and HIV-2.
The complex inhibits HIV-1 or HIV-2 infection and blocks the binding of HIV-1 or HIV-2 to the CD4 receptor and the CCR5 and CXCR4 coreceptors.
Isolated protein complexes are provided comprising Tsg101 and HIV GAG or GAGp6.
Such compounds are useful for inhibiting the infection of HIV-1 and HIV-2, the human immunodeficiency viruses that induce acquired immunodeficiency syndrome (AIDS).
The compounds inhibit the activity of human immunodeficiency virus (HIV) protease and interfere with HIV induced cytopathogenic effects in human cells.
The present invention relates to the use of synergistic combinations of nucleoside derivatives for inhibiting human immunodeficiency virus (HIV) replication, thereby limiting HIV infection.
Glycoprotein 160 obtained from Human Immunodeficiency Virus, HIV-1 strain
Glycoprotein 160 obtained from human immunodeficiency virus, HIV-1 strain
The peptides selectively inhibit retroviral proteinases (PR) such as HIV-1 PR, HIV-2 PR and EIAV PR.
The polypeptide immunologically mimics HIV endonuclease.
Also included are nucleic acid ligands to the HIV-RT, HIV-1 Rev, HIV-1 t^_a^_t^_, thrombin, and basic fibroblast growth factor proteins.
HIV testing by ELISA for HIV-1 and HIV-2 is recommended for all children.
In specific embodiments, the HIV-specific fusion protein is a multimer capable of binding an HIV particle, and is useful for the treatment of HIV infections.
The immunoassay is characterized by the coating of a solid substrate with a unique monoclonal antibody which recognizes a common antigenic determinant of a group of HIV core antigens and no HIV envelope antigens of HIV.
The present invention provides nucleic acid molecules encoding a chimeric molecule, HIV-RT/hTERT, is based on HIV-1 Reverse Transcriptase (HIV-RT) and human telomerase reverse transcriptase (hTERT) catalytic site.
Such sequences include the amino terminus of gp41 of HIV-1 and the amino terminus of gp40 of HIV-2.
Finally, the subject invention provides a method for determining the stage of an HIV-1 infection in an HIV-1-infected subject.
Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV.
The invention also provides a sensitive ELISA for the detection of HIV-2 infection and a method for discriminating between singly-infected with HIV-2 or dually-infected (HIV-I and HTV2) individuals.
In particular, the invention relates to the use of HIV-1 antigens from one clade in the prevention and/or treatment of disease associated with HIV-1 infection from a heterologous HIV-1 clade.
Disclosed are: a novel HIV-protease inhibitor; and a method for producing the HIV-protease inhibitor.
Synthetic DNA molecules encoding HIV gag and modifications of HIV gag are provided.
There is also provided a vaccine effective against HIV.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод